Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Congenital Mesoblastic Nephroma in a Premature Neonate: Should We Give Adjuvant Chemotherapy?
View through CrossRef
Congenital mesoblastic nephroma (CMN) is a rare renal tumor of infancy. Complete surgical excision is often sufficient. A premature neonate underwent left radical nephrectomy for CMN without any adjuvant therapy. Pathology was consistent with cellular type CMN. Six months postoperatively, the patient developed recurrence. He subsequently underwent re-excision without any adjuvant chemotherapy. The baby is tumor free for more than a year.
Title: Congenital Mesoblastic Nephroma in a Premature Neonate: Should We Give Adjuvant Chemotherapy?
Description:
Congenital mesoblastic nephroma (CMN) is a rare renal tumor of infancy.
Complete surgical excision is often sufficient.
A premature neonate underwent left radical nephrectomy for CMN without any adjuvant therapy.
Pathology was consistent with cellular type CMN.
Six months postoperatively, the patient developed recurrence.
He subsequently underwent re-excision without any adjuvant chemotherapy.
The baby is tumor free for more than a year.
Related Results
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer
The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer
Abstract
Background
Leukocytes play an important role in cancer development. However, the impact of chemotherapy-associated neutropenia/lymphopen...
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract
Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancers today and is expected to be the second cause of cancer death in the coming decade. M...
Long Term Persistent Alopecia and Suboptimal Hair Regrowth after Adjuvant Chemotherapy for Breast Cancer: Alert for an Emerging Side Effect: ALOPERS Observatory.
Long Term Persistent Alopecia and Suboptimal Hair Regrowth after Adjuvant Chemotherapy for Breast Cancer: Alert for an Emerging Side Effect: ALOPERS Observatory.
Abstract
Background: Since 2003, through the impetus given by Pr Erick Gamelin and the Regional Health Agency in Western France (Bretagne, Pays de Loire), a network ...
Use of Receiver Operating Characteristic (ROC) Analysis To Determine the Most Optimal Prognostic Threshold for Adjuvant! in Lymph Node Negative Breast Cancer Patients < 55 Years.
Use of Receiver Operating Characteristic (ROC) Analysis To Determine the Most Optimal Prognostic Threshold for Adjuvant! in Lymph Node Negative Breast Cancer Patients < 55 Years.
Abstract
Background: Adjuvant!1 is a web based tool to predict the 10-year relapse free survival (RFS), breast cancer specific survival (BCSS) and overall survival (...
Impact of adjuvant chemotherapy on outcomes after curative-intent surgery for biliary tract cancer: A 10-year retrospective single-center study.
Impact of adjuvant chemotherapy on outcomes after curative-intent surgery for biliary tract cancer: A 10-year retrospective single-center study.
e16273 Background: Surgical resection remains the mainstay of treatment for biliary tract cancers (BTCs). Although adjuvant capecitabine has been shown to reduce recurrence, the b...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Abstract P1-13-11: Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer
Abstract P1-13-11: Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer
Abstract
[Background]In adjuvant settings of HER2 positive cancer, trastuzumab has been shown to be effective in combination with anthracycline- based chemotherapy f...